NCT07163078Not yet recruiting
Nutrition Supplement for Cystic Fibrosis
A Medical Nutrition Supplement for Cystic Fibrosis
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The goal of this study is to learn if one nutrition supplement formula works better than a different formula in adults with cystic fibrosis. The main question being addressed is: Will certain atypical versions of certain nutrients outperform typical versions of these nutrients? This will be determined by examining blood measures of nutrient levels and/or indications of nutrient function indicators pre- and post-intervention. Participants will take the supplements for 6 weeks with a blood draw before and after that time.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 25 Jun 2025
- Start date
- 15 Oct 2026
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- Ohio State University
- Diseases
- Cystic fibrosis
- NCT number
- NCT07163078
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Oct 2026 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If patients are currently taking Category A or Category B in the LiverTox categorization system
- Patients that are on other medications that are sensitive CYP3A4 substrates - such as tacrolimus for example
Other illness
- History of liver abnormalities
Lab values
- Persistent elevation of liver enzymes \>6 months (E2) (ALT \>80 U/L)
Other
- Non-English-speaking participants
- Acute health crisis
- Recent vitamin D supplementation of 30 mcg/day or higher, vitamin E supplements of 200 IU/day or higher, or copper at 2 mg/day or higher
- Any other concern by investigator that the subject is inappropriate for inclusion
- Patients who is on a reduced dose of a CFTR modulator
- Patients on azole antifungals (voriconazole, itraconazole, posaconzole, \>7 days of fluconazole, etc.).
- Patients who binge drink EtOH - for men more than 2 drinks/day, for women more than 1 drink/ day
- Patients on sensitive CYP3A4 substrates including but not limited to tacrolimus, sirolimus, and cyclosporine
Who the study is looking for
- Diagnosed with cystic fibrosis
- Diagnosed with exocrine pancreatic insufficiency
- 18 years old or older
- Currently on modulator
- Normal liver enzyme labs
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nationwide Children's Hospital/ Ohio State University Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.